Perrigo
This article was originally published in The Tan Sheet
Executive Summary
Private labeler receives FDA clearance for acetaminophen, aspirin and caffeine tablets (ANDA 75-794) July 12. Product is first approved generic version of Bristol-Myers Squibb's Excedrin Migraine, which lost marketing exclusivity Jan. 14. Perrigo says it will not launch store brand equivalent until Spring 2002, however, as it focuses on shipping products planned before quality control problems hampered launches last year (1see item, p. 5)
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.